We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,363,424 | 16:29:57 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.67 | 67.38B |
Date | Subject | Author | Discuss |
---|---|---|---|
04/7/2018 10:14 | The immigrants voted leave in 1776. A big difference. ;)) | alphorn | |
04/7/2018 09:24 | Americans voted LEAVE in 1776 - things seem to have worked out OK for them …... | tradermichael | |
04/7/2018 09:18 | Quiet day today , US closed for Independence Day | philanderer | |
04/7/2018 09:13 | Well, a non-executive Director at that …. | tradermichael | |
03/7/2018 22:43 | I’m hoping for early retirement in my early 50s. My largest single shareholding makes about 4% of my total. I just couldn’t bear a profits warning or other adverse news that would impact my life. Of course that means I’m unlikely to experience a big positive shift either | dr biotech | |
03/7/2018 21:11 | GSK director sued over US opioid epidemic. UK pharma company removed work history at Purdue from Lewent’s biography. Non GSK stuff - Purdue Pharma, an opioid maker. | alphorn | |
03/7/2018 11:19 | 3rd july Barclays overweight tp 1750p up from 1700p | philanderer | |
03/7/2018 10:22 | Deutshe were the Analysts that forecast £1920 when the shares reached £1720. But they went dramatically in the other direction. | jadeticl3 | |
03/7/2018 09:44 | 3rd july Deutsche hold tp 1525p up from 1420p | philanderer | |
03/7/2018 08:41 | Thank you Phoenix, I will do some research into Bonds. Not something I have considered up to now, mainly through lack of knowledge of them. Happy with GSK for the moment. N.R. | nik rosa | |
02/7/2018 11:51 | Horlicks sale is mainly to pay for novertis parts they did not own,any left overs will go towards divis and other requirements | abdullla | |
02/7/2018 11:30 | UBS reiterating 'buy' | philanderer | |
02/7/2018 11:14 | Girolami put it very nicely for Glaxo when he spoke about Zantac in days gone past - "if you have all your eggs in one basket then it has to be a very good basket". GSK is a different animal today. Selling Horlicks to (partially) support the dividend sums it up. (My positions in GSK are balanced at present). | alphorn | |
02/7/2018 10:56 | @NikR This is no comment on the merits of GSK, but solely the idea of holding one stock at retirement. IMHO you are following a dangerous strategy. The usual practice as you age is to progressively de-risk a portfolio. Say you begin slowly investing aged 25, being 100% invested in a range of equities might be an appropriate strategy. One of the reasons why is at say 25 it is assumed that you have decades to survive the inevitable volatility ['time is on your side'], plus you likely have decades of employment to make up any realised losses along the way. Between your starting age and your retirement, your capacity to rebuild a portfolio or absorb medium/longer-term hits is progressively reduced. For maaany years the investment advice has been to progressively shift away from stocks into bonds. You will see this reflected in say the various Vanguard LifeStrategy investment funds. For each step [a decade or so] there is a fund aimed towards your target retirement age, the bond allocation increases across these steps. That said, it has been argued of late that given the outlook for rising interest rates, this might be precisely the wrong point of the economic cycle to be switching into [expensive] bonds. This is something I'm facing and have considered at some length. My conclusion is broadly that I'll remain 100% in stocks for the meanwhile, until later progressively de-risking towards bonds when their risks are more balanced. The concern is that your entire investment portfolio relies upon the fortunes of one company. I wonder how you sleep at night! | jrphoenixw2 | |
02/7/2018 10:24 | I too have a majority holding in GSK. Its a well-established global company with a very strong brand. UK listing often benefits from a strong US $, and is also a defensive stock in these times. Underpriced, I'd say, so opportunity for capital growth, coupled with >5% dividend (pays 4 times a year). Good luck and enjoy retirement! ;0) | tradermichael | |
02/7/2018 10:16 | It's 7 years now since retiring and entering the weird world of sharedealing on a casual basis. After much tossing/turning, wheelin'/dealin', buying/selling,my portfolio now comprises 100% GSK. Call me foolhardy if you like, but it is the only investment that has given me no significant problems and looks to have a strong future (God bless Pharma!). Happy to read conflicting (or supportive) opinions on this subject. Good luck. N.R. | nik rosa | |
02/7/2018 06:44 | Range 1488 to 1580 neutral trend | action | |
01/7/2018 10:19 | The real prescription for lower drug prices: Get Europe to drop its price controls. | xxxxxy | |
29/6/2018 11:16 | Maybe they'll do better than their last forecast... '20-Jul-17 Goldman Sachs Buy 1,625.00p [Now (ie: then)] 1,900.00p [old Target] 1,900.00p [New Target] Reiteration' | jrphoenixw2 | |
29/6/2018 10:27 | Goldmans reinitiates coverage with 'buy' and 1900p target price | philanderer | |
29/6/2018 10:26 | Goldmans reinitiates coverage with 'buy' and 1900p target price | philanderer | |
28/6/2018 19:11 | next wk will be the turning point. | action | |
28/6/2018 19:10 | TM Next wk may be the your I g point all being equal | action |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions